Short Interest in Biocept Inc (BIOC) Rises By 71.2%

Biocept Inc (NASDAQ:BIOC) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 863,632 shares, an increase of 71.2% from the February 28th total of 504,596 shares. Based on an average daily trading volume, of 2,868,031 shares, the short-interest ratio is presently 0.3 days. Approximately 7.5% of the company’s stock are sold short.

BIOC stock remained flat at $$1.02 during trading on Friday. The company had a trading volume of 667,576 shares, compared to its average volume of 2,722,119. Biocept has a fifty-two week low of $0.66 and a fifty-two week high of $12.15. The firm has a market capitalization of $19.24 million, a P/E ratio of -0.11 and a beta of 2.93. The company has a current ratio of 1.30, a quick ratio of 1.18 and a debt-to-equity ratio of 0.32.

Biocept (NASDAQ:BIOC) last released its earnings results on Thursday, March 28th. The medical research company reported ($1.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.07. Biocept had a negative return on equity of 427.45% and a negative net margin of 755.80%. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.95 million. Research analysts predict that Biocept will post -3.84 EPS for the current fiscal year.

An institutional investor recently bought a new position in Biocept stock. Dimensional Fund Advisors LP acquired a new stake in shares of Biocept Inc (NASDAQ:BIOC) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 39,445 shares of the medical research company’s stock, valued at approximately $108,000. Dimensional Fund Advisors LP owned approximately 1.74% of Biocept at the end of the most recent quarter. 1.77% of the stock is owned by institutional investors.

Several brokerages have recently commented on BIOC. Maxim Group began coverage on Biocept in a research report on Tuesday, March 26th. They issued a “buy” rating for the company. ValuEngine upgraded Biocept from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Zacks Investment Research upgraded Biocept from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Wednesday, February 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $1.25.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Recommended Story: What factors cause inflation to rise?

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.